PetLife Pharmaceuticals owns the exclusive rights to Escozine For Pets, a cancer treatment derived from blue scorpion venom. Testing confirmed that the venom of the Dominican blue scorpion contained higher concentrations of compounds like Chlorotoxin that inhibit cancer cell growth. While other products like Escozul were produced in Cuba, PetLife's patented formulation and extraction process leads to a more potent and effective treatment. PetLife established its own scorpion reservation in the Dominican Republic to independently source venom for Escozine For Pets and meet global demand for the treatment.

2. PETLIFE™ - White Paper
History of Escozine For Pets™ 1
2014
HISTORY OF ESCOZINE FOR PETS™
Table of Contents
I. Escozine For Pets™ verses Escozul / Vidatox.......................................................................2
II. Patent ................................................................................................................................................2
III. Labiofam...........................................................................................................................................2
IV. Location / Natural Habitat of the Caribbean Blue Scorpion................................................3
V. Confirmation from Atheris Laboratory, Switzerland.............................................................4
VI. Summary ..........................................................................................................................................5
(310) 279-5154
info@petlifepharma.com
www.petlifepharma.com
The information contained in this document is subject to national and International Copyright© laws and is
the proprietary and exclusive property of PetLife Pharmaceuticals, except as otherwise indicated. No part
of this document, in whole or in part, may be reproduced, stored, transmitted, or used for design purposes
without the prior written permission of PetLife Pharmaceuticals. The information contained in this document
is subject to change without notice. The information in this document is provided for informational purposes
only. Privacy Information: This document may contain information of a sensitive nature. This information
should not be given to persons other than those who are involved with PetLife Pharmaceuticals, or who will
become involved during the lifecycle.

3. PETLIFE™ - White Paper
History of Escozine For Pets™ 2
2014
A NEW CANCER FORMULATION DERIVED FROM BLUE SCORPION VENOM.
I. Escozine For Pets™ verses Escozul / Vidatox
PetLife Pharmaceuticals and its sister company, Medolife, are the only companies in the
world which have the patented formulation based upon blue scorpion venom. Medolife’s
Escozine is the first alternative natural medication recognized for oncological treatments
by the Ministry of Health, Food and Drug Administration, of the Dominican Republic.
PetLife owns the exclusive rights to all veterinary uses of the patented formulation and
technology. Although based on the same Blue Scorpion venom compound, Escozine™
and Escozine for Pets™ have many advantages over Escozul and Vidatox which are
illustrated below in the history and comparison of the products.
II. Patent
PetLife owns exclusive veterinary rights to Arthur Mikaelian’s patent which achieved a full
patent in 2012 for the bioactive peptide (Blue Scorpion Venom) and polarization
technology (Patent # US 8,097,284 B2). This unique patented polarization technique
escalates the highly positive charges in the extracellular membrane of main compounds
in Escozine For Pets™. This gives them the ability to function as a transportation
mechanism; it also intensifies the binding preferences with malignant cells.
The Patented Mikaelian Polarization technology plays an essential role in potentiating the
Blue Scorpion Venom and delivering more active ingredients directly into cancerous cells
in comparison to non-polarized ingredients. This technology allows fewer compounds to
be used and allows large scale commercialization of the natural version.
PetLife’s exclusively owned bioactive peptide (Blue Scorpion Venom) and polarization
technology for veterinary use is the base for a novel pharmacologically active compound
which is critical in numerous new generation essential drugs and Nutraceuticals for
veterinary use.
III. Labiofam
The Cuban laboratory, Labiofam, has no registration, patent or completed scientific
research regarding Escozul to make an adequately supported presentation of this product
to a regulatory agency or, for that matter, to the public. Further, actual production quality
control for medication of ESCOZUL does not exist at this time. Labiofam has completely
stopped the production of Escozul and it has been replaced by Vidatox, which is a
homeopathic version which has been diluted 1:1,000. We have a spectrophotometer
analysis of Vidatox which shows no evidence of venom.
The website, www.escozul-cancer.com, contains useful technical and scientific
information regarding Escozul. However, it also simultaneously posts misleading

4. PETLIFE™ - White Paper
History of Escozine For Pets™ 3
2014
information alleging (with noticeable exaggeration) that Labiofam is the “only” company
who is entitled to engage in the research and production of Escozul. In fact, the
Guantanamo group as specifically mentioned in this website is the original group who
initiated the blue scorpion medication project. The former leader was Michel Bordier, the
scientist who discovered the effect of blue scorpion venom. The Guantanamo group has
more case studies and experience with blue scorpion venom than Labiofam. However,
the Guantanamo group is presented on the website as a company who does not possess
the right or knowledge to conduct research and development of Escozul. Dr. Mikaelian
was present and indeed witnessed Labiofam doctors employing statistical analyses and
protocols created by the Guantanamo group. After the death of Michel Bordier, the
Guantanamo group stopped being active and they lost their position as a leading research
group. Michel Bordier did not apply for any patent or any legal registration or claims.
This is only one of many distortions of the real facts regarding the origin, development
and sale of Escozul. Collectively these distortions appear to be an actively orchestrated
propaganda campaign to promote Labiofam as the only legitimate provider of Escozul.
Beyond the obvious, it would appear these misrepresentations benefit the tourist
economy of Cuba. Since Labiofam was not free to market its product internationally and
was not prepared to meet the demands of ongoing production and distribution, significant
numbers of tourists used to travel to Cuba to receive the medication, under the false belief
that it is free. The actual cost of Escozul under these circumstances was prohibitive for
most of the general public, who have need of it.
IV. Location / Natural Habitat of the Caribbean Blue Scorpion
Another significant misstatement made on the website is that the blue scorpions only
inhabit the island of Cuba. Medolife has scientific proof that proves that this is false. A
scorpion which is identical to the Cuban blue scorpion has been confirmed to inhabit the
Dominican Republic. The technical name of the Cuban blue scorpion is Rhopalurus
junceus (Buthidae family); and the technical name of the Dominican blue scorpion is
Rhopalurus princeps (also Buthidae family). Cuban biologists Armas and Prendini have
confirmed that these scorpions are of the same species. Additionally, this has been
confirmed by Atheris Laboratory in Switzerland.
Rhopalurus princeps, (Karsch, 1879)
By: Michiel Cozijn
“Morphological Information Rhopalurus princeps seems more closely
related to the Cuban
Rhopalurus species (Prendini et al, 2009).”
See http://www.ntnu.no/ub/scorpion-files/r_princeps_biography.pdf.

5. PETLIFE™ - White Paper
History of Escozine For Pets™ 4
2014
In 2007 Medolife signed a contract with the Ministry of Environment of Dominican
Republic and started expeditions and located Rhopalurus princeps with local scientist and
biologist Kelvin A. Guerrero.
See Kelvin A. Guerrero’s. website: 2007-2011: Consultant Entomologist and Research
Advisor for Medolife Corporation for the research: Investigation on the Biochemistry and
Ecology of the Species of Scorpion of the Family Buthidae in the Dominican Republic in
order to identify potential organic of the scorpion venom compound that can be beneficial
to cure cancer disease on human.
The source: http://kguerrero.net/consulting.html
V. Confirmation from Atheris Laboratory, Switzerland
In 2009, the venom of Rhopalurus junceus (Cuban blue scorpion) and the venom of
Rhopalurus princeps (Dominican Republic blue scorpion) were sent by Medolife to
Switzerland's world famous Atheris laboratory (http://atheris.com) for identification of
these two venoms. (As background, Atheris laboratory helped Trans-molecular Inc. to
identify Chlorotoxin, one of the main components in Buthidae family scorpion venom. See
the following links to obtain more details and information regarding this study.
http://en.wikipedia.org/wiki/Chlorotoxin and http://www.transmolecular.com)
Atheris Laboratory has provided scientific confirmation to Medolife that both scorpion
venoms block sodium and potassium volt gate channels. (Please read letter reprinted
below from Atheris.) This action causes actual shrinkage of tumors and inhibits cancer
cell proliferation. Interestingly, the report (MALDI-TOF-MS) analyses from Atheris
laboratory indicates that Dominican blue scorpion venom has a three times higher
concentration of Chlorotoxin, which is one of the main components with anti tumoral
properties and also has smaller molecular weight than the Cuban blue scorpion venom,
which makes Escozine For Pets™ more effective in the penetration of cancer cell
membranes and more therapeutic compound passes through the blood–brain barrier
(BBB).

6. PETLIFE™ - White Paper
History of Escozine For Pets™ 5
2014
The following is a copy of the letter from Atheris Laboratory: <See the original letter
attached>
Dear Arthur Grant Mikaelian PhD,
Please find attached both certificates of analysis concerning Rhopalurus
princeps and R. junceus.
These analyses allowed the detection of numerous components in both
venoms. Spectra clearly display signals that are consistent with scorpion
venoms with two major sets of masses, the first one located around 3-4 kDa
(mainly potassium channel inhibitors) and the second one at 6-8 kDa
(mostly sodium channel inhibitors).
We hope these analyses correspond to your expectations.
Best regards,
Philippe Favreau
03/30/2010
Philippe Favreau
Atheris Laboratories
CP 314
1233 Bernex - Geneva
Tel: 0041 22 850 05 85
Fax: 0041 22 850 05 86
PetLife note: The “two certificates’ referenced directly contain information deemed
proprietary and are not included in this White Paper. Select prospective partners or investors
may be granted access to the certificates, for due diligence purposes, under NDA.
VI. Summary
Dr. Mikaelian is currently the only scientist who has completed all research and the
development process and has attained the legal registration to commercialize the Blue
Scorpion venom based product. This patent and technology has been licensed to PetLife
Pharmaceuticals for commercialization.
Escozine For Pets™ is solely owned and commercialized by PetLife Pharmaceuticals.
PetLife’s sister company, Medolife, owns and markets the human product, Escozine. The
product, Escozul, is not produced or sold by Medolife and neither Medolife nor PetLife
rely on this product in any way.

7. PETLIFE™ - White Paper
History of Escozine For Pets™ 6
2014
PetLife in association with Medolife has its own independent source of Blue Scorpion
venom in the Dominican Republic and has established the world’s first Scorpion
reservation which is 50,000 square meters and can produce millions of doses to meet
global demand.

8. PETLIFE™ - White Paper
History of Escozine For Pets™ 7
2014